# Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

> **NCT05776979** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 61 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Isatuximab
- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT05776979
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-17
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2025-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05776979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05776979, "Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05776979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*